• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.

作者信息

Marques E, Arenberger P, Smetanová A, Gkalpakiotis S, Zimová D, Arenbergerová M

机构信息

Department of Dermatovenereology, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic.

Department of Neurology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic.

出版信息

Br J Dermatol. 2021 May;184(5):966-967. doi: 10.1111/bjd.19716. Epub 2021 Feb 1.

DOI:10.1111/bjd.19716
PMID:33301601
Abstract
摘要

相似文献

1
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.抗肿瘤坏死因子α治疗失败后，使用司库奇尤单抗成功治疗顽固性化脓性汗腺炎。
Br J Dermatol. 2021 May;184(5):966-967. doi: 10.1111/bjd.19716. Epub 2021 Feb 1.
2
Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa.使用肿瘤坏死因子-α阻滞剂进行旋转疗法治疗顽固性化脓性汗腺炎。
Eur J Dermatol. 2010 Sep-Oct;20(5):644-6. doi: 10.1684/ejd.2010.1037. Epub 2010 Jul 9.
3
Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.肿瘤坏死因子-α抑制剂治疗化脓性汗腺炎：英夫利昔单抗的最新进展
Acta Derm Venereol. 2011 Jan;91(1):70-1. doi: 10.2340/00015555-0989.
4
Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures.在抗TNF和抗白细胞介素-17治疗失败后，司库奇尤单抗对一例顽固性化脓性汗腺炎的疗效。
Dermatol Ther. 2021 Nov;34(6):e15116. doi: 10.1111/dth.15116. Epub 2021 Sep 7.
5
Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?化脓性汗腺炎：肿瘤坏死因子-α阻滞剂是最终的选择吗？
Br J Dermatol. 2008 Sep;159(3):761-3. doi: 10.1111/j.1365-2133.2008.08735.x. Epub 2008 Jul 9.
6
Treatment of moderate to severe hidradenitis suppurativa.中重度化脓性汗腺炎的治疗。
Ann Intern Med. 2013 Jul 2;159(1):72. doi: 10.7326/0003-4819-159-1-201307020-00015.
7
Treatment of moderate to severe hidradenitis suppurativa.中度至重度化脓性汗腺炎的治疗。
Ann Intern Med. 2013 Jul 2;159(1):72-3. doi: 10.7326/0003-4819-159-1-201307020-00016.
8
Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.阿达木单抗治疗常规治疗失败后的难治性化脓性汗腺炎：长期有效控制。
Int J Dermatol. 2010 Dec;49(12):1445-9. doi: 10.1111/j.1365-4632.2010.04638.x.
9
[Hidradenitis suppurativa. Response to treatment with infliximab].[化脓性汗腺炎。英夫利昔单抗治疗反应]
Actas Dermosifiliogr. 2007 Jun;98(5):325-31.
10
Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.患者摘要。阿达木单抗用于治疗化脓性汗腺炎。
Ann Intern Med. 2012 Dec 18;157(12):I-50. doi: 10.7326/0003-4819-157-12-201212180-00001.

引用本文的文献

1
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
2
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
3
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.
化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
4
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
5
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.阿达木单抗治疗化脓性汗腺炎时出现矛盾性银屑病样反应：真实世界经验及对其他生物制剂的治疗反应。
Dermatol Ther. 2022 Dec;35(12):e15866. doi: 10.1111/dth.15866. Epub 2022 Oct 13.
6
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
7
Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series.司库奇尤单抗治疗化脓性汗腺炎的疗效和安全性：病例系列
Acta Derm Venereol. 2022 Sep 28;102:adv00780. doi: 10.2340/actadv.v102.2926.
8
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.
9
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.
10
Insights into the Pathogenesis of HS and Therapeutical Approaches.化脓性汗腺炎发病机制及治疗方法的见解。
Biomedicines. 2021 Sep 6;9(9):1168. doi: 10.3390/biomedicines9091168.